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Edited by Robert BaroukiAbstract In endothelial cells cultured under high glucose condi-
tions, methylglyoxal is themajor intracellular precursor in the for-
mation of advanced glycation endproducts. We found that
endothelial cells incubated with 30 mM D-glucose produced
approximately 2-fold higher levels of methylglyoxal but not 3-
deoxyglucosone and glyoxal, as compared to 5 mM D-glucose.
Under hyperglycaemic conditions, the methylglyoxal-arginine
adduct argpyrimidine as detected with a speciﬁc antibody, but not
Ne-(carboxymethyl)lysine and Ne-(carboxyethyl)lysine, was signiﬁ-
cantly elevated. The glyoxylase I inhibitorHCCGand the PPARc
ligand troglitazone also increased argpyrimidine levels. Increased
levels of argpyrimidine by glucose, HCCG and troglitazone are
accompanied by a decrease in proliferation of endothelial cells.
A 27 kDa protein was detected as a major argpyrimidine-modiﬁed
protein.With in-gel digestion andmass spectrometric analysis, we
identiﬁed this major protein as heat-shock protein 27 (Hsp27).
This argpyrimidine modiﬁcation of Hsp27 may contribute to
changes in endothelial cell function associated to diabetes.
 2006 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Prolonged exposure to hyperglycaemia has detrimental eﬀects
on endothelial cell function and is the primary causal factor in
the majority of diabetic complications [1,2]. A potential mecha-
nism by which hyperglycaemia and its immediate biochemical
sequelae induce damage in endothelial cells includes an in-
creased formation of advanced glycation endproducts (AGEs)
[3]. AGEs are formed from the reaction of glucose and other
reducing sugars with amino groups of proteins. AGEs can beAbbreviations: AGEs, advanced glycation endproducts; Hsp27, heat-
shock protein 27; HUVEC, human umbilical cord vein endothelial
cells
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doi:10.1016/j.febslet.2006.01.086formed extracellularly, but it is now apparent that intracellular
sugars and their derivatives can participate in glycation and
AGE formation [4], as was initially demonstrated for growth
factors [5]. In endothelial cells, the highly reactive dicarbonyl
compound methylglyoxal has been identiﬁed as a major precur-
sor in the formation of intracellular AGEs [6]. Methylglyoxal is
formed non-enzymatically by dephosphorylation of triose phos-
phates and is eﬃciently catabolised to D-lactate by the glyoxa-
lase pathway, consisting of glyoxalase I and glyoxalase II and
the cofactor glutathione [7].
Methylglyoxal reacts with arginine residues to form the non-
ﬂuorescent products 5-hydro-5-methylimidazolone, tetrahydro-
pyrimidine and the major ﬂuorescent product argpyrimidine[8].
Plasma concentrations ofmethylglyoxal [9] aswell as 5-hydro-5-
methylimidazolone [10] and argpyrimidine [8] are increased in
diabetic patients. Furthermore, the presence of argpyrimidine
has been demonstrated in human lenses, in human atheroscle-
rotic lesions and in the arterial wall of kidneys of diabetic pa-
tients [8,11]. Although it has been reported that methylglyoxal
primarily reacts with arginine, the methylglyoxal-lysine adducts
Ne-(carboxyethyl)lysine, imidazolysine and methylglyoxal-
derived lysine dimer MOLD have also been identiﬁed [12,13].
Methylglyoxal is involved in a variety of detrimental pro-
cesses such as cell growth arrest, dysfunction, apoptosis and
necrosis, most probably mediated through modiﬁcations of
proteins [7,14]. Since these events are closely related to the
development and progression of diabetes complications, it is
of importance to identify the proteins that are modiﬁed by
methylglyoxal. In this study we demonstrated in human endo-
thelial cells that hyperglycaemia produced higher levels of
methylglyoxal. Under these conditions, argpyrimidine is signif-
icantly elevated. We identiﬁed heat-shock protein 27 (Hsp27)
as the major argpyrimidine-modiﬁed protein.2. Materials and methods
2.1. Materials
M199, heat-inactivated newborn calf serum (NBCS), foetal calf serum
(FCS) and glutamine were purchased fromBioWhittaker (Verviers, Bel-
gium). Human serum (HS) and pyrogen-free human serum albumin
were obtained from Sanquin Research (Amsterdam, the Netherlands),
penicillin/streptomycin from Gibco (Breda, the Netherlands), and hep-ation of European Biochemical Societies.
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was purchased from Merck (Darmstad, Germany). Crude endothelial
cell growth factor was prepared from bovine brain [15]. Monoclonal
mouse anti-argpyrimidine IgGwas fromDr. K.Uchida and was charac-
terised before. Monoclonal mouse-anti-Hsp27 IgG was purchased from
Cell Signalling (Beverly, MA, USA) and polyclonal goat anti-Hsp27
IgG was from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
2.2. Cell culture
Human umbilical cord vein endothelial cells (HUVECs) were iso-
lated from umbilical cords according to Jaﬀe et al. [16]. The cells were
seeded onto 1% gelatine coated dishes and were cultured in M199, sup-
plemented with 10% heat-inactivated NBCS, 10% HS, 1% glutamine,
penicillin (100 U/ml) streptomycin (10 lg/ml), heparin (5 U/ml) and
endothelial cell growth factor (150 lg/ml) and were kept at a constant
temperature of 37 C in an incubator under 5% CO2 and 20% O2 atmo-
sphere.
2.3. Cell proliferation assay
HUVEC were pre-cultured in 24-well plates (Greiner bio-one) with 5
or 30 mM D-glucose for 48 h. 18 h prior to harvesting, [3H] thymidine
(1 lCi/ml; Amersham Biosciences, Baie d’Urfe, Canada) was added
and the incorporation into newly synthesised DNA was determined
as described.2.4. Preparation of anti-methylglyoxal antibodies
Methylglyoxal-keyhole limpet hemocyanin (KLH) was prepared by
the reaction of methylglyoxal (10 mM) with KLH for 7 days at 37 C
and was used as antigen for the immunisation of mice. Methylglyoxal-
KLH was emulsiﬁed in an equal volume of Freund’s complete adju-
vant and three mice were intradermally injected at multiple sites. The
mice were boosted with the same amount of methylglyoxal-KLH emul-
siﬁed in Freund’s incomplete adjuvant 21 days later and antisera ob-
tained 14 days after the booster were tested. The booster was
repeated twice. Ten days after the ﬁnal booster, antisera were tested
with methylglyoxal-albumin and the mouse with the highest titer was
used for fusion. We obtained 40 positive clones as tested with methyl-
glyoxal-albumin and one of them was further characterised. This
monoclonal antibody was from the IgG1 subclass, and has an at least
10-fold preference for tetrahydropyrimidine as compared to argpyrim-
idine or 5-hydro-5-methyl-4-imidazolone. Details of the characterisa-
tion of this antibody will be described elsewhere.2.5. Western blotting
HUVECs were lysed in ice-cold lysis buﬀer (PBD, 1% Triton X-100,
12 mM sodiumdeoxycholate and 0.1% sodium dodecyl sulfate) with a
cocktail of protease inhibitors (Roche) and subsequently sonicated.
Equal amounts of protein, as determined using the Bradford protein
assay (Bio-Rad, Munchen, Germany), from cells incubated under dif-
ferent conditions were used. The lysates were separated by 12% SDS–
PAGE and then transferred electrophoretically to a PVDF membrane.
The membrane was incubated for 1 h at room temperature with the
primary antibody (anti-argpyrimidine, 1:200000; anti-tetrahydropyr-
imidine, 1:2000, anti-Hsp27, 1:10000). Then the membrane was
washed three times and incubated for 1 h at room temperature with
HRP-conjugated goat anti-mouse IgG (Dako, 1:2000). HRP was visu-
alised by the ECL plus detection system (Amersham Biosciences).
2.6. Analysis of 1,2-dicarbonyl compounds and AGEs
HUVECs cultured in 25 cm2 ﬂasks were washed with ice-cold PBS
and scraped in 200 ll acetic acid (0.1 M) and homogenised by sonica-
tion. The concentrations of methylglyoxal, 3-deoxyglucosone and gly-
oxal were determined by reversed-phase HPLC with gradient elution
after derivatisation to their respective dimethoxyquinoxaline deriva-
tives as recently described [17]. Concentrations of CML and CEL were
measured by stable-isotope dilution tandem mass spectrometry (API
3000 from Sciex/Applied Biosystems) as recently described [18].
2.7. Two-dimensional gel electrophoresis
Two-dimensional gel electrophoresis was carried out. In brief, endo-
thelial cells were solubilised in lysis buﬀer for 30 min (9 M urea, 2%
CHAPS, 20 mM Tris, pH 7.5, 0.5% dithiothreitol, and 0.5% IPG buﬀer3–10) and then centrifuged. 370 ll of the supernatant was used for the
rehydration and simultaneously loading of the proteins to the IPG
strip (Immobiline 18 cm DryStrip 3–10 NL, Amersham Biosciences),
at 30 V for 12 h. The voltage was increased to 8000 V and focused
for a total of 65000 V/h. Immediately after being focused, IPG strips
were wrapped in plastic foil and stored at 80 C. Prior to SDS–
PAGE, IPG strips were equilibrated in 6 M urea/2% SDS/1% dithio-
threitol/50 mM Tris, pH 8.8/30% glycerol for 15 min, followed by
equilibration in 6 M urea/2% SDS/2.5% iodoacetamide/50 mM Tris,
pH 8.8/30% glycerol for 15 min. The second dimension separation
was run overnight using the Isodalt System (Amersham Biosciences)
in 1.5-mm 11% gels (Duracryl, Genomic Solutions) at 25 mA per gel
at 15 C. After electrophoresis, a gel was ﬁxed and stained using silver.
The gel was washed once with water and stored at room temperature in
a plastic sealing until tryptic digestion. A gel, which was run in parallel,
was subjected to Western-blotting and immunostained with anti-arg-
pyrimidine.
2.8. Digestion of proteins from two-dimensional gels
The corresponding immunopositive argpyrimidine spot from the sil-
ver-stained gel was manually excised with a round bottom dermal sli-
cer of 3-mm diameter. The gel pieces were destained in 60% acetonitrile
in 25 mM ammonium bicarbonate buﬀer, pH 8.5, and then dehydrated
with 100% acetonitrile. The shrunken gel pieces were re-swelled in
25 mM ammonium bicarbonate buﬀer, dehydrated again in 100% ace-
tonitrile, and dried in a speedvac. The gel pieces were rehydrated in 8 ll
of trypsin solution (20 lg/ml) for 1 h, followed by addition of 50 ll of
25 mM ammonium bicarbonate buﬀer to completely immerse the gel
pieces. After incubation overnight at room temperature, the superna-
tant was loaded into a self-packed Poros R2 (PerSeptive Biosystems)
micro-tip, and eluted in 5 ll 50% acetronitrile/1% formic acid directly
into a spraying electrode and analysed by an electrospray Q-TOF
(Micromass) mass spectrometer.
2.9. Immunoprecipitation
HUVECs were lysed in lysis buﬀer. The lysate was incubated with
agarose conjugated with goat anti-Hsp27 antibody as prepared with
the Immunolink Plus Immobilization Kit (Pierce, Rockford, USA).
Western blot analysis of the lysate before and after immunoprecipita-
tion was performed with mouse anti-Hsp27 and anti-argpyrimidine as
described above.
2.10. Data presentation and statistics
Data are expressed as mean ± S.D. The n values represent number of
independent experiments with three determinations within one experi-
ment. Statistical diﬀerences were determined using paired 2-tailed Stu-
dent’s t test. A P < 0.05 was considered to be statistically signiﬁcant.3. Results
3.1. Methylglyoxal is signiﬁcantly elevated in endothelial cells
cultured under hyperglycaemic conditions
Human endothelial cells cultured under hyperglycaemic con-
ditions (30 mM D-glucose, 96 h) induced an increase in the
concentrations of methylglyoxal as compared to cells cultured
under standard conditions (5 mM D-glucose) (Fig. 1). Under
the same experimental conditions we did not ﬁnd a signiﬁcant
increase of 3-deoxyglucosone and glyoxal (under standard
condition the concentrations were 0.012 and 0.085 nmol/mg
protein, respectively) and also not of the AGEs CML and
CEL (under standard conditions 0.07 and 0.01 lmol/mmol ly-
sine, respectively). Simultaneously, the proliferation of endo-
thelial cells was reduced (Fig. 2). To evaluate whether an
intracellular formation of methylglyoxal is associated with a
reduction in cell proliferation, we treated endothelial cells with
a direct inhibitor of glyoxalase I, the HCCG-diester, or the
PPARc ligand troglitazone, which has been reported to be a
potential inhibitor of glyoxalase I synthesis inside cells [19].
Fig. 1. Methylglyoxal concentrations in HUVECs cultured under
normo- and high glucose conditions. HUVECs were cultured under
standard conditions (5 mM D-glucose), 15 mM D-glucose and 30 mM
D-glucose for 4 days. Cells were scraped in acetic acid (0.1 M) and the
methylglyoxal concentrations in cell extracts were measured by HPLC,
as described in Section 2. Data are the means ± S.D. of four
independent experiments *P < 0.01.
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duced the proliferation by approximately 80%. In agreement
with the data on [3H]-thymidine incorporation, cell counting
as estimated by phase contrast microscopy also revealed com-
parable lower cell numbers after incubation with high glucose
(30 mM) concentrations, but also with HCCG and troglitaz-
one. Under the above mentioned conditions, we did not ob-
serve morphological diﬀerences of the cells, or an eﬀect of
cell adhesion.
3.2. MGO-adduct argpyrimidine in endothelial cells
In order to study the formation of speciﬁc methylglyoxal-ad-
ducts, we have used two monoclonal antibodies. HUVECs cul-
tured under hyperglycaemic conditions show elevated levels of
argpyrimidine at a protein of a molecular weight of 25 kDa
as compared to cells cultured under normoglycaemic condi-
tions (Fig. 3B). In contrast, an antibody with a preference
for tetrahydropyrimidine above argpyrimidine and 5-hydro-
5-methylimidazole did not show such a diﬀerence in endothe-
lial cells cultured under identical conditions (Fig. 3A). Cells
treated with troglitazone, or HCCG-diester also showed signif-
icantly higher levels of argpyrimidine (Fig. 3B). Under thesecontrol HCCG troglitazone
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Fig. 2. The eﬀect of high glucose concentrations, HCCG and
troglitazone on HUVEC proliferation. HUVECs were cultured under
5 mM D-glucose or 30 mM D-glucose for 4 days, without or with the
glyoxalase I inhibitor (HCCG-diester, 48 h, 5 lM) or troglitazone
(24 h, 0.1 mM). The [3H] thymidine incorporation into newly synthe-
sized DNA of endothelial cells was evaluated. Means ± S.D. of four
independent experiments are given; *P < 0.05, **P < 0.01 vs. control
(5 mM D-glucose).conditions, we did not ﬁnd changes in the free methylglyoxal
concentration (data not shown).
Cells cultured under hyperglycaemic conditions have signif-
icantly higher levels of argpyrimidine compared to cells cul-
tured under normoglycaemic conditions (Figs. 3B and 4), but
in time, the argpyrimidine levels inside cells decreased
(Fig. 4), whereas the absolute diﬀerence between normoglyca-
emia and hyperglycaemia remained the same. The decrease of
argpyrimidine inside endothelial cells, as estimated in four
independent experiments, was approximately 15% per day.
3.3. Identiﬁcation of argpyrimidine-positive protein and Hsp27
in endothelial cells
To identify the major argpyrimidine-containing 25 kDa pro-
tein, we subjected cell lysates from HUVECs to two-dimen-
sional electrophoresis. One gel was used for Western blotting
and stained with an antibody against argpyrimidine. Two pro-Fig. 3. Methylglyoxal-modiﬁed proteins in endothelial cells. Western-
blot detection of tetrahydropyrimidine-containing proteins (upper
panel) and argpyrimidine-containing proteins (lower panel) in lysates
of endothelial cells, cultured under diﬀerent conditions as indicated in
the ﬁgure. Left panels: standard albumin and a MGO-albumin
preparation. Right panels, lanes 1 and 2: cells cultured under standard
conditions of 5 mM glucose (lane 1) or high glucose (30 mM D-glucose,
lane 2) for 6 days. Lanes 3 and 4: cells cultured in medium with 20%
FCS (lane 3), and 100 lM troglitazone (lane 4) for 24 h. Lanes 5 and 6:
cells cultured under standard conditions without (lane 5) and with
5 lM HCCG for 54 h (lane 6). The molecular weights of the protein
standards in kilodaltons are indicated. MGO-albumin (0.1 lg) is used
as the positive control and migrated at a molecular weight of 69 kDa.
For all conditions, 10 lg of cellular protein are used.
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Fig. 4. Western blot of Argpyrimidine containing proteins in
HUVECs. HUVECs were cultured under standard conditions (5 mM
D-glucose) or at a high glucose concentration (30 mM D-glucose) for 7,
11 and 16 days. Cell lysates were detected for the presence of
argpyrimidine by Western blotting. For all conditions, 10 lg of cellular
protein is used. The molecular weights of the protein standards in
kilodaltons are indicated. MGO-albumin (0.1 lg) is used as the
positive control and migrated at a molecular weight of 69 kDa. This
is a representative experiment out of series of four experiments with
identical results.
IMMUNODETECTION:      Hsp27 argpyrimidine
Hsp27 IMMUNOPRECIPITATION: – + – +
Fig. 6. Identiﬁcation of Hsp27 as an argpyrimidine-containing protein
in HUVEC A lysate of endothelial cells was immunoprecipitated with
antibodies against Hsp27 that was covalently coupled to agarose.
Western blot analysis was performed on the supernatant before and
after Hsp27 immunoprecipitation followed by immunodetection with
antibodies against Hsp27 (left panel) and argpyrimidine (right panel).
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phorylated and the unphosphorylated form of the protein
(Fig. 5B). Subsequently, the other gel was silver-stained and
one of the corresponding protein spots were removed from
the gel and subjected to MALDITOF (Fig. 5A). The protein
was identiﬁed as Hsp27. Western-blotting and immunodetec-
tion conﬁrmed this ﬁnding (Fig. 5C). To prove that Hsp27 is
the major argpyrimidine-containing protein, we performed
immunoprecipitation experiments. A lysate of the endothelial
cells was used for immunoprecipitation with agarose-coupled
anti-Hsp27. Western blot analysis showed that argpyrimidine
completely co-immunoprecipitated with Hsp27 (Fig 6), identi-
fying the argpyrimidine-containing protein as Hsp27.4. Discussion
Vascular endothelial cells exposed to high glucose concen-
trations might causes endothelial cell activation and, as a con-ARGPYRIM
IMMUNODET
SILVER-STAINING
Fig. 5. Identiﬁcation of argpyrimidine-positive protein and co-localisation w
used for two-dimensional electrophoresis. A gel was silver-stained and a s
argpyrimidine. After detection, the same immunoblot was stripped and staine
protein (marked) was subjected to MALDITOF.sequence, diabetic vascular complications. Studies in
endothelial cells under high glucose conditions have exempli-
ﬁed the key biochemical pathways leading to endothelial
dysfunction, including the accumulation of methylglyoxal-
mediated formation of AGEs [3]. In this study, we demon-
strated in human endothelial cells that high concentrations
of D-glucose induced higher levels of methylglyoxal, but not
glyoxal and 3-deoxyglucosone. With the use of a speciﬁc
monoclonal antibody, we demonstrated that under these con-
ditions the methylglyoxal-arginine adduct argpyrimidine was
signiﬁcantly increased, but not the methylglyoxal-lysine adduct
CEL and CML, the latter in accordance with previous results
[6]. In agreement with our result, it has been demonstrated that
high concentrations of glucose also increased the concentra-
tion of methylglyoxal in transformed fetal bovine aortic endo-
thelial cells [6] and induced synthesis of argpyrimidine in rat
retinal endothelial cells [20] and rat measangial cells [23]. In
addition to high glucose concentrations, we demonstrated that
the glyoxalase I inhibitor HCCG also increased the levels of
argpyrimidine in endothelial cells. Furthermore, the PPARc
agonist troglitazone, which has been demonstrated to down-
regulate glyoxalase I mRNA in human astroglioma cells, rat
cardiac myocytes and rat hepatocytes [19] also increased arg-
pyrimidine production.IDINE
ECTION
Hsp27
IMMUNODETECTION
ith Hsp27. A cell lysate of 300 lg of total protein from HUVEC was
econd gel was subjected to Western blotting and stained with anti-
d with an antibody against Hsp27. The corresponding immunopositive
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we did not ﬁnd changes in the free methylglyoxal concentra-
tion upon treatment of endothelial cells with HCCG and trog-
litazone. These experiments are in agreement with experiments
in endothelial cells with glyoxalase 1 overexpression in which
the levels of AGEs, but not free methylglyoxal, are decreased
[6]. It might be that HCCG and troglitazone increases free
methylglyoxal, which is immediately quenched by an interac-
tion with proteins (such as to Hsp27) and therefore not found
in its free form.
Since an increase of argpyrimidine levels upon treatment of
endothelial cells with high D-glucose concentrations, HCCG or
troglitazone are accompanied by impaired proliferation of
these cells, these data suggest that methylglyoxal and/or meth-
ylglyoxal-adducts play a critical role herein. However, it
should be emphasised that other pathways may also contribute
to proliferation such as the activation of protein kinase C [21],
which may act in concert with the MGO-modiﬁcation of
Hsp27. Brownlee and co-workers previously demonstrated
that hyperglycaemia rapidly increases intracellular AGE for-
mation in bovine aortic endothelial cells and they identiﬁed ba-
sic ﬁbroblast growth factor (bFGF) as a protein modiﬁed by
glycation [5]. Cytosolic AGE-bFGF was increased 6-fold
accompanied by a marked decrease in mitogenic activity [5].
Although these data are consistent with the hypothesis that
non-enzymatic glycation of intracellular protein alters vascular
cell function, so far neither the identiﬁcation of the glycation
of bFGF nor the identiﬁcation of other intracellular proteins
modiﬁed by glycation are identiﬁed. With immunoprecipita-
tion and immunoblotting we did not ﬁnd bFGF as an argpyr-
imidine-modiﬁed protein (data not shown), indicating that
other AGE-modiﬁcations on bFGF may be present.
In this study we identiﬁed with the use of speciﬁc antibodies
and MALDITOF, that Hsp27 in human endothelial cells is a
major argpyrimidine-modiﬁed protein. Although to a lesser ex-
tent, other proteins are modiﬁed as well (Figs. 3 and 4). Identi-
ﬁcation of these proteins was not successful, most probably due
to the detection limit of the techniques. It should be empha-
sised, however, that other proteins may also be targets for
methylglyoxal binding with the formation of other methylgly-
oxal-arginine adducts such as 5-hydro-5-methylimidazolone.
Recently, argpyrimidine formation in Hsp27 has also been
identiﬁed in human carcinoma cells [22] and rat kidney mesan-
gial cells [23], indicating that Hsp27 is a protein highly suscep-
tible for methylglyoxal modiﬁcation. Hsp27 is expressed
throughout the body and plays a role in important cellular
functions such as apoptosis [24] and actin polymerization
[25]. In stressed cells, increased levels of Hsp27 facilitate the re-
pair or destruction of damaged proteins, thus promoting cell
recovery. Because methylglyoxal modiﬁcations of Hsp27 en-
hances the chaperone function of Hsp27, like that of a-crystal-
lin [22,26] it has been speculated that methylglyoxal could
protect cells against hyperglycaemia-induced damage in diabe-
tes. Additionally, it has also been shown that Hsp27 can inhi-
bit caspase-3 activity by binding to cytochrome c. A study in
human carcinoma cells indicated that the methylglyoxal-in-
duced modiﬁcation Hsp27 is essential for oligomerisation of
Hsp27, binding of Hsp 27 to cytochrome c and, subsequently,
the protection of caspase-3 dependent cell death [22].
Taken together, we identiﬁed in human endothelial cell
Hsp27 as a major argpyrimidine-modiﬁed protein. Although
we do not know yet the role of this argpyrimidine modiﬁcationof Hsp27 in human endothelial cells, this major AGE adduct
may be associated with vascular complications in diseases such
as in diabetes.References
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